Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
411 These findings indicate that targeting tolerizing mechanisms, rather than directly suppressing inflammatory pathways, could provide promising therapeutic strategies for controlling uncontrollable infections
Kailera IPO'd in 2025 with HRS9531 (dual GLP-1/GIP, Phase 3 China readout ~17.7% weight loss February 2026) as its lead asset and HRS-4729 (the triple agonist) as an earlier-stage follow-on
Every 0.1 mL (10 units) equals exactly 100 mcg
Our emotional and physical systems are not separate
US$ 22.79
![Delta Sleep-Inducing Peptide [DSIP] | 62568-57-4](https://www.biosynth.com/storage/ChemAxonStructureImages/FD/10/FD108702_structure.png)
US$ 20.09
US$ 24.36
US$ 27.69
US$ 26.33
US$ 25.83
US$ 26.18
US$ 22.54
